Bhavik Shah, MD
Urology · Stockbridge, GANPI 1265774863
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,421 of the $33,238 with a category attached, or 64.4%. Coloplast accounts for 80.6% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2024 at $23,405 and has fallen 94.1% since, to $1,374 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $85.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$27K
- Endo Pharmaceuticals Inc.$1K
- Boston Scientific$825
- Astellas Pharma US Inc$642
- Teleflex LLC$571
- Medtronic$467
- plus $3K from 33 others
What the payments were for
- Consulting fees$21,42164%
- Travel & lodging$1,9846%
- Food & beverage$8,81427%
- Education$1,0193%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 163 | $26,783 |
| Endo Pharmaceuticals Inc. | 33 | $1,151 |
| Boston Scientific | 30 | $825 |
| Astellas Pharma US Inc | 32 | $642 |
| Teleflex LLC | 7 | $571 |
| Medtronic(2 entities) | 17 | $467 |
| Dendreon Pharmaceuticals LLC | 5 | $366 |
| Sumitomo Pharma America, Inc. | 17 | $312 |
| Bayer | 11 | $207 |
| Neotract Inc. | 4 | $145 |
| Myriad Genetic Laboratories, Inc. | 2 | $130 |
| Metuchen Pharmaceuticals | 1 | $121 |
| Innovation Technologies Inc | 1 | $120 |
| Convatec Inc. | 3 | $109 |
| Urovant Sciences Inc | 6 | $109 |
| AbbVie(2 entities) | 4 | $103 |
| Merck | 4 | $95 |
| Endo USA, Inc. | 4 | $88 |
| Johnson & Johnson | 1 | $87 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $77 |
| Tempus AI, Inc | 3 | $74 |
| Immunitybio, Inc. | 1 | $61 |
| Pfizer | 3 | $51 |
| AstraZeneca | 3 | $50 |
| Tolmar Pharmaceuticals, Inc. | 2 | $44 |
| Travere Therapeutics, Inc. | 9 | $44 |
| Novartis | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 3 | $43 |
| Laborie Medical Technologies Corp. | 3 | $42 |
| Myovant Sciences Inc. | 2 | $41 |
| Antares Pharma, Inc. | 2 | $39 |
| Rigicon,inc. | 2 | $39 |
| Tolmar, Inc. | 1 | $32 |
| Verity Pharmaceuticals Inc. | 1 | $29 |
| Acerus Pharmaceuticals Corporation | 2 | $23 |
| Blue Earth Diagnostics | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Rochester Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,238 in reported general payments places this provider in the 90th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 11 | $160,571 |
| OrgovyxRelugolix | 43 | $106,739 |
| MyrbetriqMirabegron | 85 | $83,429 |
| GemtesaVibegron | 71 | $76,725 |
| Solifenacin Succinate | 115 | $7,032 |
| Tamsulosin Hcl | 500 | $4,889 |
| Methenamine Hippurate | 35 | $2,961 |
| Estradiol | 50 | $2,948 |
| Silodosin | 27 | $2,876 |
| Finasteride | 159 | $1,823 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 59 | $1,550 |
| Testosterone Cypionate | 34 | $1,435 |
| Desmopressin Acetate | 20 | $1,146 |
| Cefdinir | 82 | $909 |
| Oxybutynin Chloride ErOxybutynin Chloride | 29 | $617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $312 | $183,464114 claims |
| Johnson & JohnsonErleada | $87 | $160,57111 claims |
| Astellas Pharma US IncMyrbetriq | $642 | $83,42985 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 369 urology providers in Georgia.
Other urology in Stockbridge
- Jonathan ZurawinStockbridge$34K
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Scott MillerRoswell$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.